The DEA (US drug enforcement agency) will announce at least two enforcement actions against clinics operating without proper registration or licenses to give psychedelic drugs. This matters because as states create new psilocybin and ketamine clinics, many operators skip DEA paperwork, and the agency needs to show it's still relevant and enforcing rules.
As state-level psilocybin and ketamine clinic expansion accelerates without consistent DEA registration compliance, the agency faces institutional pressure to assert enforcement relevance amid rescheduling debates. Selective high-profile actions are standard DEA playbook during regulatory transition periods. This is falsifiable via public DEA press releases, court filings, or DOJ announcements.